Journals in Pharmacology

11-20 of 72 results in All results

Comparative Biochemistry and Physiology - Part A: Molecular & Integrative Physiology

ISSN: 1095-6433
5 Year impact factor: 2.3
Impact factor: 2.3

Comparative Biochemistry & Physiology (CBP) publishes papers in comparative, environmental and evolutionary physiology. Part A: Molecular and Integrative Physiology (CBPA), focuses on physiological systems, including behavior, circulation, development, excretion, ion regulation, endocrinology, locomotory, nervous, nutrition, respiration, and thermal biology. Most studies address regulatory mechanisms and span multiple levels of biological organization. All four CBP journals support and follow the editorial direction from all the major societies in the field: Australia & New Zealand Society of Comparative Physiology and Biochemistry (ANZSCPB) American Physiological Society (APS) Canadian Society of Zoologists (CSZ) Deutsche Zoologische Gesellschaft (DZG) European Society of Comparative Physiology and Biochemistry (ESCPB) Japanese Society for Comparative Physiology and Biochemistry (JSCPB) South American Society for Comparative Physiology and Biochemistry (SASCPB) Societe de Physiologie (SDP) Society for Experimental Biology (SEB) Society for Integrative & Comparative Biology (SICB) Benefits to authors CBP journals are focused on promoting the authors and the work published in the journal: All articles are carefully evaluated directly by the Editors-in-Chief who are leading experts in their field. Availability: contact the Editor-in-Chief for any questions you may have. The Journal will provide upon request free PDFs to all authors who may not have access to their articles via their institution or library. Publication is free to authors (no color or page charges). Supporting open access: if your funding body or institution requires your article to be open access, CBP offers that option. Please see details here. Reuse figures from any CBP article via "get rights and content" hyperlink available within each article (below author names and affiliations) on ScienceDirect. Please click here for more information on more general author services. Other CBP journals Part B (CBPB): Biochemistry & Molecular Biology Part C (CBPC): Toxicology & Pharmacology Part D (CBPD): Genomics & Proteomics

Comparative Biochemistry and Physiology - Part A: Molecular & Integrative Physiology

Comparative Biochemistry and Physiology - Part C: Toxicology & Pharmacology

ISSN: 1532-0456
5 Year impact factor: 3.8
Impact factor: 3.9

Comparative Biochemistry & Physiology (CBP) publishes papers in comparative, environmental and evolutionary physiology. Part C: Toxicology and Pharmacology (CBPC), focuses on toxicological mechanisms at different levels of organization, primarily chemical and drug action, biotransformation of xenobiotics, endocrine disruptors, nanoparticles, pharmaceuticals, and natural products chemistry. Most studies employ a molecular approach in combination with observations of higher levels of organization to assess the mechanism by which xenobiotics affect physiology. Analytical verification of exposure concentrations is strongly recommended for manuscripts reporting toxicological studies. All four CBP journals support and follow the editorial direction from all the major societies in the field: Australia & New Zealand Society of Comparative Physiology and Biochemistry (ANZSCPB) American Physiological Society (APS) Canadian Society of Zoologists (CSZ) Deutsche Zoologische Gesellschaft (DZG) European Society of Comparative Physiology and Biochemistry (ESCPB) Japanese Society for Comparative Physiology and Biochemistry (JSCPB) South American Society for Comparative Physiology and Biochemistry (SASCPB) Societe de Physiologie (SDP) Society for Experimental Biology (SEB) Society for Integrative & Comparative Biology (SICB) Benefits to authors CBP journals are focused on promoting the authors and the work published in the journal: All articles are carefully evaluated directly by the Editors-in-Chief who are leading experts in their field. Availability: contact the Editor-in-Chief for any questions you may have. The Journal will provide upon request free PDFs to all authors who may not have access to their articles via their institution or library. Publication is free to authors (no color or page charges). Supporting open access: if your funding body or institution requires your article to be open access, CBP offers that option. Please see details here. Reuse figures from any CBP article via "get rights and content" hyperlink available within each article (below author names and affiliations) on ScienceDirect. Please click here for more information on more general author services. Other CBP journals Part A (CBPA): Molecular & Integrative Physiology Part B (CBPB): Biochemistry & Molecular Biology Part D (CBPD): Genomics & Proteomics

Comparative Biochemistry and Physiology - Part C: Toxicology & Pharmacology

Comparative Biochemistry and Physiology - Part D: Genomics and Proteomics

ISSN: 1744-117X
5 Year impact factor: 3.2
Impact factor: 3

Comparative Biochemistry & Physiology (CBP) publishes papers in comparative, environmental and evolutionary physiology. Part D: Genomics and Proteomics (CBPD), focuses on “omics” approaches to physiology, including comparative and functional genomics, metagenomics, transcriptomics, proteomics, metabolomics, and lipidomics. Most studies employ “omics” and/or system biology to test specific hypotheses about molecular and biochemical mechanisms underlying physiological responses to the environment. We encourage papers that address fundamental questions in comparative physiology and biochemistry rather than studies with a focus that is purely technical, methodological or descriptive in nature. All four CBP journals support and follow the editorial direction from all the major societies in the field: Australia & New Zealand Society of Comparative Physiology and Biochemistry (ANZSCPB) American Physiological Society (APS) Canadian Society of Zoologists (CSZ) Deutsche Zoologische Gesellschaft (DZG) European Society of Comparative Physiology and Biochemistry (ESCPB) Japanese Society for Comparative Physiology and Biochemistry (JSCPB) South American Society for Comparative Physiology and Biochemistry (SASCPB) Societe de Physiologie (SDP) Society for Experimental Biology (SEB) Society for Integrative & Comparative Biology (SICB) Benefits to authors CBP journals are focused on promoting the authors and the work published in the journal: All articles are carefully evaluated directly by the Editors-in-Chief who are leading experts in their field. Availability: contact the Editor-in-Chief for any questions you may have. The Journal will provide upon request free PDFs to all authors who may not have access to their articles via their institution or library. Publication is free to authors (no color or page charges). Supporting open access: if your funding body or institution requires your article to be open access, CBP offers that option. Please see details here. Reuse figures from any CBP article via "get rights and content" hyperlink available within each article (below author names and affiliations) on ScienceDirect. Please click here for more information on more general author services. Other CBP journals Part A (CBPA): Molecular & Integrative Physiology Part B (CBPB): Biochemistry & Molecular Biology Part C (CBPC): Toxicology & Pharmacology

Comparative Biochemistry and Physiology - Part D: Genomics and Proteomics

Contemporary Clinical Trials

ISSN: 1551-7144
5 Year impact factor: 2.2
Impact factor: 2.2

Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome. The following topics are covered in the journal: Unconventional design features of specific trials and their rationale Preliminary or full results of clinical trials with unconventional design features Statistical methods for all aspects of clinical trials Methodologies for clinical trial operations including trial management and optimization; patient recruitment and retention; and trial quality monitoring and assessment Data management methodologies including data collection; database maintenance; data quality assurance; safety monitoring and risk management; and patient registries Regulatory requirements and their impact on clinical trials Ethical and legal considerations in clinical trials Risk-benefit, cost-effectiveness and decision analyses in clinical trials Contemporary Clinical Trials is unique in that it is outside the confines of disease specifications, and it strives to adapt and grow with an expanding clinical trials landscape as the needs of clinical research evolve in today's dynamic healthcare environment. Having taken upon the important role as a platform for knowledge exchange between experts in different disciplines related to clinical trials, the ultimate goal of Contemporary Clinical Trials is to advance this field of research for the benefit of patients. We look forward to receiving your contribution! Authors are also welcome to submit to the journal's open access companion title, Contemporary Clinical Trials Communications. Benefits to authors Contemporary Clinical Trials also provides many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Contemporary Clinical Trials Communications

ISSN: 2451-8654
5 Year impact factor: 1.8
Impact factor: 1.5

This companion title to Contemporary Clinical Trials is an international peer reviewed open access journal that publishes articles pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted to Contemporary Clinical Trials Communications should appeal to a readership drawn from a wide range of disciplines including medicine, life science, pharmaceutical science, biostatistics, epidemiology, computer science, management science, behavioral science, and bioethics. Contemporary Clinical Trials Communications is unique in that it is outside the confines of disease specifications, and it strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings irrespective of their perceived importance, significance or impact. Both randomized and non-randomized trials are within the scope of the Journal. Some common topics include trial design rationale and methods, operational methodologies and challenges, and positive and negative trial results. In addition to original research, the Journal also welcomes other types of communications including, but are not limited to, methodology reviews, perspectives and discussions. Through timely dissemination of advances in clinical trials, the goal of Contemporary Clinical Trials Communications is to serve as a platform to enhance the communication and collaboration within the global clinical trials community that ultimately advances this field of research for the benefit of patients.

Contemporary Clinical Trials Communications

Contraception

ISSN: 0010-7824
5 Year impact factor: 2.9
Impact factor: 2.9

An international reproductive health journalThe Official Journal of the Society of Family Planning Contraception has an open access companion journal Contraception: X which has the same aims and scope, editorial board and peer-review process. To submit to Contraception: X visit https://www.editorialmanager.com/conx/default.aspx The journal Contraception wishes to advance reproductive health through the rapid publication of the best and most interesting new scholarship regarding contraception and related fields such as abortion. The journal welcomes manuscripts from investigators working in the laboratory, clinical and social sciences, as well as public health and health professions education.Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Current Opinion in Pharmacology

ISSN: 1471-4892
5 Year impact factor: 4.8
Impact factor: 4

Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance. COPHAR is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Pharmacology and Drug Discovery (CRPHAR). COPHAR divides the subject of pharmacology into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance. Themes include neurosciences; cardiovascular and renal; respiratory; musculoskeletal; cancer; immunomodulation; anti-infectives; new technologies; gastrointestinal; endocrine; and metabolic diseases. The journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. Expertise - Expert authors, who are leaders in their field, are invited to write short review articles in which they present recent developments in their subject and provide short annotations to the papers that they think are most relevant. Comprehensiveness - There are 27 high-impact Current Opinion review journals in a range of subjects from food science to green and sustainable chemistry. Impact - In addition to a vast readership, Current Opinion titles enjoy high citations, Impact Factors, and CiteScores. Selection of topics to be reviewed Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected. Reviews Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year. Editorial Overview Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments. Ethics in Publishing: General Statement The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict. For more information, please refer to: https://www.elsevier.com/conflictsofinterest

Current Research in Pharmacology and Drug Discovery

ISSN: 2590-2571

Current Research in Pharmacology and Drug Discovery (CRPHAR) is a new primary research, gold open access journal from Elsevier. CRPHAR publishes original papers, reviews, graphical reviews, short communications and follow-up manuscripts resulting from research in pharmacology and drug discovery that cover aspects of drug action at the cellular, molecular, and biochemical level. Current Research in Pharmacology and Drug Discovery is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Pharmacology (2020 Journal Impact Factor 5.547, CiteScore 9.3) and is part of the Current Opinion and Research (CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow. Current Research in Pharmacology and Drug Discovery topics covered include neuropharmacology (psychiatry and neurodegeneration); sensory pharmacology (ocular, auditory and pain); cardiovascular; renal; respiratory; musculoskeletal; cancer; immunopharmacology (inflammation and innate immune system function); anti-infectives; gastrointestinal; endocrine; metabolic; systems pharmacology and signalling; drug metabolism; pharmaceutics and drug delivery; pharmacogenetics; analytical toxicology; pharmacokinetics; new technologies; and translational and clinical pharmacology. Current Research in Pharmacology and Drug Discovery builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. Expertise - Editors and Editorial Board bring depth and breadth of expertise and experience to the journal. Speed - Submission and peer review is fast, and publication of final manuscripts is instantaneous. Discoverability - Articles get high visibility and maximum exposure on an industry-leading platform that reaches a vast global audience. Ethics in Publishing: General Statement The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. For more information, please refer to: https://www.elsevier.com/conflictsofinterest

Current Therapeutic Research

ISSN: 0011-393X
5 Year impact factor: 2
Impact factor: 1.9

Current Therapeutic Research (CTR) is a multidisciplinary, peer-reviewed Open Access journal focusing on the discovery, development, and use of therapeutics and interventions across all therapeutic areas and all aspects of therapy. It is read by a large international audience of scientists and healthcare professionals in various research, academic, and clinical practice settings. Articles published in CTR are indexed by all major biomedical abstracting databases (e.g., PubMed/Medline, Clarivate, Scopus). CTR aims to publish high-quality, rigorous, and ethically sound original research, be it positive, confirmatory, or negative data, with the goal of improving healthcare. The journal welcomes in-depth review articles, meta-analyses, commentaries, brief reports, case reports, research letters, and letters to the editor. CTR promotes collaborative and interdisciplinary work with objectivity, criticism, creativity, innovation, and respect for cultural and professional diversity. By doing so, the journal provides a communication space for all therapists, regardless of their discipline or specialty. CTR areas of interest: Experimental medicine and therapeutics, translational medicine, clinical use of medicines and safe medication prescribing. Topics related to new or existing drug pharmacology, such as pharmacotherapy, pharmacovigilance, pharmacoeconomics, pharmacoepidemiology, personalized medicine and ethnopharmacology. Pharmaceutical topics including clinical trials, medicinal chemistry, drug disposition and effects, pharmaceutical medicine, pharmacodynamics, pharmacokinetics and toxicology. Pharmacometrics: PK/PD modeling, PBPK modeling, clinical trial modeling and simulation. Complementary medicine and therapies topics, including natural or herbal medicines that complement or replace conventional therapies - biological mechanisms of action, efficacy, safety, costs, patterns of use and implementation. Studies relating to stem-cell and nutritional therapy, diagnostics and diagnosis, public health, quality of life, patient care, management, and education are also encouraged. Interventions focused on all aspects of clinical therapy, including non-pharmacological ones. Emphasis will be placed on studies of specific topics such as pediatric clinical trials and pediatric and maternal-fetal pharmacology and toxicology. Research may involve preclinical and clinical studies and utilize both in vitro and in vivo approaches. Please note that the journal does not publish research on traditional medicines (e.g., traditional Chinese medicine, Kampo medicine, a Japanese traditional medicine) or studies involving crude natural products. Finally, CTR promotes inclusion and diversity by considering submissions from all over the world, whether they relate to an international or a country-specific audience (e.g., a specific patient population). Submit your manuscript at https://www.editorialmanager.com/curtherres.

Currents in Pharmacy Teaching and Learning

ISSN: 1877-1297
5 Year impact factor: 1.7
Impact factor: 1.2

Currents in Pharmacy Teaching and Learning is devoted to dissemination of high quality, peer-reviewed scholarship relevant to all areas of pharmacy education—promoting educational research excellence. The Journal maintains a particular focus in two major areas: pharmacy faculty development in the scholarship of teaching and learning and the scholarship of interprofessional pharmacy education. With diverse editorial board members, authors, and peer reviewers, the Journal engages a variety of stakeholders in pharmacy education: educators, researchers, faculty practitioners, as well as interprofessional colleagues. Diverse author contributions are within original research, review articles, commentaries, and letters categories. Original research topics include, but are not limited to: Scholarship of Teaching and Learning: teaching/learning strategies; interprofessional education Quality Improvement - assessment of programmatic/curricular outcomes Curricular Revision – design, implementation, evaluation New school/program strategies Attitudes/perceptions within pharmacy education